Toinv

Thanks for the comprehensive analysis on shareholder ownership and votes. Given the ownership you have detailed, Hepas near majority position, RVXs lack of resources, another trial needed for fda approval - this could be the last dance.

DM has his back against the wall.

The catch22 royalty sale strategy, ie., sell royalties on prospective future sales which would be enabled by positive results from a registration enabling trial paid for by the sale of the future royalties is a desperate financing effort. He made his case at the AGM. This methodology would be nondilutive and could possibly generate enough capital to pay off the existing debenture and secure the encumbered IP.

Either an outright sale of RVX or obtain trial financing. The clock is ticking. RVX is broke. DM could be working for Hepa next year.

RVXCF closed at .057US Friday

Chicagoest